Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan.
Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan.
Sci Rep. 2020 Dec 18;10(1):22343. doi: 10.1038/s41598-020-79242-w.
Despite efficient and specific in vitro knockdown, more reliable and convenient methods for in vivo knockdown of target genes remain to be developed particularly for retinal research. Using commercially available and chemically modified siRNA so-called Accell siRNA, we established a novel in vivo gene silencing approach in the rat retina. siRNA designed for knockdown of the house keeping gene Gapdh or four retinal cell type-specific genes (Nefl, Pvalb, Rho and Opn1sw) was injected into the vitreous body, and their retinal mRNA levels were quantified using real-time PCR. Intravitreal injection of siRNA for Gapdh resulted in approximately 40-70% reduction in its retinal mRNA levels, which lasted throughout a 9-day study period. Furthermore, all the selected retinal specific genes were efficiently down-regulated by 60-90% following intravitreal injection, suggesting injected siRNA penetrated into major retinal cell types. These findings were consistent with uniform distribution of a fluorescence-labeled siRNA injected into the vitreous body. Interestingly, gene silencing of Grin1, a core subunit of NMDA receptor, was accompanied by significant prevention from NMDA-induced retinal ganglion cell death. Thus, we provide single intravitreal injection of Accell siRNA as a versatile technique for robust and sustainable in vivo retinal gene silencing to characterize their biological functions under physiological and pathophysiological conditions.
尽管在体外进行高效和特异性的基因敲低已经取得了很大的进展,但对于视网膜研究而言,仍需要开发更为可靠和方便的体内基因敲低方法。本研究利用市售的、经过化学修饰的 siRNA(即 Accell siRNA),在大鼠视网膜中建立了一种新的体内基因沉默方法。设计用于敲低管家基因 Gapdh 或四种视网膜细胞类型特异性基因(Nefl、Pvalb、Rho 和 Opn1sw)的 siRNA 被注射到玻璃体腔中,并用实时 PCR 定量检测其视网膜 mRNA 水平。玻璃体腔注射 Gapdh 的 siRNA 可使视网膜中 Gapdh 的 mRNA 水平降低约 40-70%,并持续整个 9 天的研究期。此外,玻璃体腔注射后,所有选定的视网膜特异性基因均被有效下调 60-90%,提示注射的 siRNA 可以穿透到主要的视网膜细胞类型中。这些发现与注射到玻璃体腔中的荧光标记 siRNA 的均匀分布一致。有趣的是,NMDA 受体核心亚基 Grin1 的基因沉默伴随着 NMDA 诱导的视网膜神经节细胞死亡的显著预防。因此,我们提供了单次玻璃体腔注射 Accell siRNA 的方法,作为一种通用技术,可用于在生理和病理生理条件下对视网膜基因进行稳健且可持续的体内基因沉默,以研究其生物学功能。